WAYNE, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Ringer™ Perfusion Balloon Catheter (PBC), the only commercially available Percutaneous Transluminal Coronary Angioplasty (PTCA) perfusion balloon.1 "The Ringer PTCA Clinical Study demonstrated that inflation of the Ringer™ PBC for 60 seconds or more was well tolerated in the majority of patients who ...

QuikClot™ Hemostatic Dressings and Devices control bleeding faster than standard gauze or laparotomy pads,1-3 enabling clinicians to move patients to the next stage of care quickly. The portfolio includes a range of products to support clinicians throughout the hospital, including in the Emergency Department, Operating Room, Intensive Care Unit, and Catheterization Lab. Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 300,000 other providers ...

Premier's SURPASS® program is designed to drive the highest-level commitment and savings for members through aggregated purchasing of high-quality products and services. The program brings together Premier's most committed members to coordinate purchasing decisions and maintain standardization across their facilities. By providing additional value to Premier contracted suppliers through volume and commitment, the program is expected to achieve best-in-market pricing. "QuikClot™ Hemostatic Dressings and the ...

Teleflex (TFX) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and fu ...

Core Viewpoint - Teleflex Incorporated has established the Teleflex Center for Antimicrobial Protection (TCAP) to enhance its Vascular Access business unit, focusing on reducing infections related to vascular access procedures [1][6]. Group 1: Company Overview - Teleflex is a global provider of medical technologies, offering a diverse portfolio that includes trusted brands such as Arrow™, Barrigel™, and QuikClot™ [3][9]. - The company aims to improve health and quality of life through innovative solutions in various therapy areas, including anesthesia, emergency medicine, and vascular access [9]. Group 2: TCAP Initiatives - TCAP is dedicated to combating infections caused by multidrug-resistant organisms, often referred to as "superbugs," which can complicate patient care and extend hospital stays [6]. - The center focuses on education and partnerships with healthcare professionals to serve as a resource for infection prevention [6][7]. - TCAP recently sponsored an educational webinar on healthcare-acquired infections, specifically targeting central line-associated bloodstream infections (CLABSI) [2][6]. Group 3: Product Offerings - Teleflex's Arrow™ brand features a comprehensive portfolio of antimicrobial Chlorhexidine catheters that provide broad-spectrum protection against various pathogens [8]. - The company also offers Arrow™ Maximal Barrier Kitting options to enhance patient protection and improve procedural efficiency for clinicians [8].

WAYNE, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, August 1, 2024. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginn ...

WAYNE, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, August 1, 2024. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginn ...

Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements. Most Powerful Force Impacting Stock Prices Harnessing the Power of Earnings Estimate Revisions Earnings Estimate Revisions for Teleflex Analysts ...

Investors with an interest in Medical - Instruments stocks have likely encountered both Teleflex (TFX) and SONOVA HOLDING (SONVY) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank emphasizes companies with positive estimat ...

Hims & Hers Health's earnings are expected to surge 272.7% in 2024 compared with the industry's 16.6%. HIMS' earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. Its shares have surged 136.4% against the industry's 28% decline in the past year. HIMS sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. Medpace, carrying a Zacks Rank #2 (Buy) at present, has an estimated 20 ...